Future Cardia

YC Dropout raises $13M to take on the $110B market with AI-powered implantable devices

Print
Claim My Business
Categories
Technology, Financial Services, Healthcare & Medical
Min Investment
$100
Location
Safety Harbor, FL
Expected Close Date
April 30, 2025
Target Raise
$50.00K-$2.50M
No. Investors
344
Security Price
$3
Number of Employees
8
Cash
$2,157,697
Revenue
$0
Short Term Debt
$140,484
Cost of Goods
$0
Long Term Debt
$698,106
Net Income
$-3,502,822

Key Deal Facts

Backed by Sand Hill Angels (SweetGarden, Ro, Masterclass, Parsley Health and many other major exits)
Incubated by Johnson & Johnson JLABS, accelerated by Stanford’s StartX
Multiple exits & two IPOs achieved by team of experts from Medtronic, Boston Scientific, Stanford
39 devices implanted in 2024 at world-renowned medical centers
60,000+ hours of cardiac data powering AI insights
$110B implantable medical device market
Forecasting $40M+ in revenue within 5 years
Limited players, Premium Pricing. High value to patients and physicians with simplicity and accuracy

Management Team / Advisory Board Bios

VC-Backed
Raised $250K or more from a venture firm, Jaeson Bang Founder & CEO Cardiology & medtech startup trailblazer. 20+ years of experience in clinical, business and tech operations at Silicon Valley startups and Medtronic and Abiomed. $13M raised from angel investors. Northwestern University, Kellogg School of Management MBA., Anatoly Yakovlev, PhDData ScientistBiomedical engineer & AI maestro. Neuro-modulations and machine learning expert. Leading AI innovations at Oracle (NYSE: ORCL). Stanford University PhD., Adam GullicksonVP of OperationsMedtech leader & regulation guru. R&D, manufacturing, quality, and regulatory expert with 21 years experience. Specializes in navigating regulatory pathways to lead teams to market. University of Minnesota, Biomedical Engineering., Steve ZielinksiVP of Systems Engineering and SoftwareMedical device R&D veteran. 20+ years of experience. Expert in systems development and AI applications. Led the development of Coloplast's first active implantable neuromodulation device. University of Minnesota BEE, University of St. Thomas MSDD., Dimitrios Georgakopoulos, PhDScience AdvisorHeart health expert & seasoned medtech scientist. 25+ years of expertise in heart failure and cardiac hemodynamics. Former Chief Science Officer at Sunshine Heart Inc. (NASDAQ: SSH). Johns Hopkins University PhD., Dr. Dan Burkhoff, MD PhDMedical AdvisorWorld-renowned cardiologist & scientist. Leader in heart failure and medtech startups with multiple exits. Former VP at Heartware ($1.2B acquisition by Medtronic). Columbia University MD PhD., Dr. Kevin Heist, MD PhDMedical AdvisorLeading cardiologist & electrophysiology, currently Associate Professor at Harvard Medical School Special focus on treating cardiac arrhythmias at Mass General Hospital in Boston. Stanford University MD PhD., Dr. Toshi Okabe, MDMedical AdvisorElectrophysiology cardiologist & arrhythmia specialist. Expertise in cardiac arrhythmia management and performing cardiac ablations. Practicing cardiologist at Ohio State University. University of Tokyo MD.
Amount Raised : $4,051,208
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Research Reports

No reports have been submitted

Become a Reporter

0 Comments